NCT03433027 - A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 12, 2018

Study Completion Date

April 6, 2020

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

BB-401

BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks

Trial Locations (6)

The Chris O'Brien Lifehouse, Camperdown

Calvary Central Districts Hospital, Elizabeth Vale

Irkutsk Oncology Center, Irkutsk

Clinical Oncology Dispensary #1, Krasnodar

Leningrad Regional Oncology Dispensary, Leningrad Region

Saint Petersburg City Oncology Clinic, Saint Petersburg